On May 21, Dr. Hunter Song, Vice Chairman of TIANS Group, was officially appointed Director of ISPE China (International Society for Pharmaceutical Engineering). As a core think tank leading global pharmaceutical engineering standards, members of the ISPE China Council are all industry leaders with outstanding contributions and profound influence in global or regional pharmaceutical engineering. Dr. Song’s appointment not only represents international recognition of his professional expertise in biomedical engineering, but also demonstrates TIANS Group’s leading position in advanced pharmaceutical processes and high‑level compliance design. Chinese pharmaceutical engineering capabilities represented by TIANS are fully integrating with and empowering the high‑standard development of the global pharmaceutical industry.

Photo | Certificate of Dr. Hunter Song for ISPE China Council Membership

On the same day, the 2026 ISPE China Annual Conference grandly opened. Dr. Hunter Song attended the opening ceremony and took the stage alongside numerous heavyweight industry guests, including Mr. Mark Hernick, Chief Operating Officer & Chief Financial Officer of ISPE, Mr. Marcus Ray from the FDA China Office, Mr. Zhao Qing of ISPE Shanghai Office, Mr. Zheng Leiming, Chairman of ISPE China Council, Ms. Liu Shanshan of the ISPE Global Board of Directors, and Mr. Christian Wölbeling, primary author of the ISPE Pharma 4.0 Guidelines, to jointly launch the annual conference. Witnessed by all participants, the conference officially kicked off.

Photo | Dr. Hunter Song (1st from left) at the launch ceremony of the 2026 ISPE China Annual Conference

Dr. Song shared his profound outlook on his new role and the future of the industry. He stated: “China’s biomedical industry is currently at a critical leap‑forward stage toward global innovation and high‑level compliance. Being appointed Director of ISPE China is not only an honor, but also a heavy industry responsibility. Going forward, drawing on my experience in biomedical planning and leveraging ISPE’s global professional platform, I will actively promote deep integration and seamless alignment of cutting‑edge domestic and international technologies, fully support more Chinese pharmaceutical enterprises to cross international compliance thresholds, and contribute more Chinese wisdom and solutions to the global pharmaceutical arena.”

TIANS Group has long been committed to providing full‑life‑cycle consulting, design, engineering and validation services for pharmaceutical enterprises. Dr. Hunter Song’s new appointment will further deepen TIANS’ collaboration with top global professional organizations. In the future, TIANS Group will proactively benchmark and participate in the formulation and promotion of international pharmaceutical engineering standards, fully act as a bridge linking Chinese pharmaceutical engineering technologies with the highest global standards, and inject strong momentum into the internationalization and technological transformation of China’s pharmaceutical industry.

About ISPE

Founded in 1980 and headquartered in the United States, the International Society for Pharmaceutical Engineering (ISPE) is a world‑leading industry organization in the field of pharmaceutical engineering. With more than 25,000 pharmaceutical experts across over 120 countries, it aims to elevate engineering and manufacturing standards throughout the pharmaceutical value chain through technology leadership, standard‑setting, education & training, and industry exchanges. Its guidelines such as Good Engineering Practice (GEP) and Baseline Guides are regarded as key industry references. ISPE China operates a Shanghai Office dedicated to serving members in China and the Asia‑Pacific region. Its branch council oversees organizational development and high‑quality academic platforms.

Dr. Hunter Song is a renowned expert in biomedical consulting and planning, Director of ISPE China, and Executive Member of the Pharmaceutical Technology Committee of China Medical Education Association. He boasts extensive international experience in biopharmaceuticals, synthetic biology, food and healthcare industries, with solid practical expertise and forward‑looking, innovative concepts in industrial planning & design, process development, technology commercialization, conceptual and engineering design, and product commercialization. He has led numerous large‑scale projects, including the new pre‑filled formulation line project for Shenzhen Hepalink Pharmaceutical (winner of the 2026 ISPE Facility of the Year Award (FOYA)), the ADC & DS4 Workshop Project and Shanghai Innovation Center Project for BeiGene, university biomedical technology transfer centers, the high‑end green adhesive industrialization base for Henkel, the CNS recombinant drug R&D and production base for Luye Jiaao, and the anti‑cancer drug production base construction project for Guangzhou Nuocheng Jianhua.